Results 81 to 90 of about 36,463 (268)

Non-destructive assessment of cannabis quality during drying process using hyperspectral imaging and machine learning

Frontiers in Plant Science
Cannabis sativa L. is an industrially valuable plant known for its cannabinoids, such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), renowned for its therapeutic and psychoactive properties.
Hyo In Yoon, Su Hyeon Lee, Dahye Ryu, Hyelim Choi, Soo Hyun Park, Je Hyeong Jung, Ho-Youn Kim, Jung-Seok Yang   +7 more
doaj   +1 more source

Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)*

Journal of Biological Chemistry, 2015
Background: Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate endocannabinoid tone in vivo through unknown mechanisms. Results: THC and CBD bind to fatty acid-binding proteins (FABPs) and reduce endocannabinoid metabolism.
Matthew W. Elmes, Martin Kaczocha, William T. Berger, KwanNok Leung, Brian P. Ralph, Liqun Wang, Joseph M. Sweeney, J. Miyauchi, S. Tsirka, I. Ojima, D. Deutsch   +10 more
semanticscholar   +1 more source

Exploring Linalool‐Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition

Phytotherapy Research, EarlyView.
Schematic overview of the proposed neuromodulatory actions of linalool in Alzheimer's disease. Through multi‐target effects on oxidative stress, amyloid aggregation, GABAergic and glutamatergic signaling, linalool may restore excitatory/inhibitory balance.
Ilaria Piccialli, Giovanni Roviello, Giorgia Magliocca, Emilia Esposito, Anna Pannaccione   +4 more
wiley   +1 more source

Synthese Pyridin-analoger Tetrahydrocannabinol / Synthesis of Pyridine-analogous Tetrahydrocannabinols

Zeitschrift für Naturforschung B, 1979
Abstract Starting from 4-methylpyridine a 3-aza-Δ8 -tetrahydrocannabinol-analogous (2d) was prepared. The reaction sequence also includes the first synthesis of a 6 H-benzo(4,5)-pyrano(2,3-c)-pyridin-6-on, a novel ring-system. The proposed structures were supported by spectroscopic data (1 H NMR, IR, MS).
Friedhelm Lötz, Udo Kraatz, Friedhelm Körte   +2 more
openaire   +1 more source

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors

PLoS Biology, 2015
Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents ...
X. Viñals, E. Moreno, L. Lanfumey, A. Cordomí, A. Pastor, R. de la Torre, P. Gasperini, Gemma Navarro, L. Howell, L. Pardo, C. Lluis, E. Canela, P. McCormick, R. Maldonado, P. Robledo, E. Nestler   +15 more
semanticscholar   +1 more source

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Cannabis Use in Pregnant and Breastfeeding Women: Behavioral and Neurobiological Consequences

Frontiers in Psychiatry, 2020
Nowadays, cannabis is the most consumed illicit drug. The global prevalence of the use of cannabis in 2017 was estimated in 188 million of people, 3.8% of worldwide population.
Francisco Navarrete, Francisco Navarrete, María Salud García-Gutiérrez, María Salud García-Gutiérrez, Ani Gasparyan, Ani Gasparyan, Amaya Austrich-Olivares, Teresa Femenía, Teresa Femenía, Jorge Manzanares, Jorge Manzanares   +10 more
doaj   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors

Molecules, 2020
Cannabis is widely used as a therapeutic drug, especially by patients suffering from psychiatric and neurodegenerative diseases. However, the complex interplay between phytocannabinoids and their targets in the human receptome remains largely a mystery ...
Yi Yang, Rupali Vyawahare, Melissa Lewis-Bakker, Hance A. Clarke, Albert H. C. Wong, Lakshmi P. Kotra   +5 more
doaj   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source